Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.
Dabei Tang, Jianli Ma, Zhong Chu, Xiaowei Wang, Wenhui Zhao, Qingyuan Zhang
Abstract
through inactivation of NF-κB signaling pathways, providing a rationale for the combined use of apatinib and DOX in TNBC chemotherapy.
Topics & Concepts
ApatinibDoxorubicinCancer researchTriple-negative breast cancerApoptosisIn vivoMedicineCancerCancer cellBreast cancerPharmacologyChemistryChemotherapyBiologyInternal medicineBiochemistryBiotechnologyChemotherapy-induced cardiotoxicity and mitigationCancer Treatment and PharmacologySynthesis and biological activity